Seelos Therapeutics, Inc is a biotechnology business based in the US. Seelos Therapeutics shares (SEEL) are listed on the NASDAQ and all prices are listed in US Dollars. Seelos Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Seelos Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SEEL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Seelos Therapeutics stock price (NASDAQ: SEEL)Use our graph to track the performance of SEEL stocks over time.
Seelos Therapeutics shares at a glance
|Latest market close||$3.08|
|52-week range||$0.56 - $6.60|
|50-day moving average||$2.79|
|200-day moving average||$3.60|
|Wall St. target price||$9.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.81|
Buy Seelos Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Seelos Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Seelos Therapeutics price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||9.22%|
|3 months (2021-05-03)||-47.35%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Seelos Therapeutics financials
|Gross profit TTM||$-10,984,000|
|Return on assets TTM||-67.21%|
|Return on equity TTM||-211.8%|
|Market capitalisation||$243.8 million|
TTM: trailing 12 months
Shorting Seelos Therapeutics shares
There are currently 4.0 million Seelos Therapeutics shares held short by investors – that's known as Seelos Therapeutics's "short interest". This figure is 19.5% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting Seelos Therapeutics shares can be evaluated.
Seelos Therapeutics's "short interest ratio" (SIR)
Seelos Therapeutics's "short interest ratio" (SIR) is the quantity of Seelos Therapeutics shares currently shorted divided by the average quantity of Seelos Therapeutics shares traded daily (recently around 4.2 million). Seelos Therapeutics's SIR currently stands at 0.94. In other words for every 100,000 Seelos Therapeutics shares traded daily on the market, roughly 940 shares are currently held short.
However Seelos Therapeutics's short interest can also be evaluated against the total number of Seelos Therapeutics shares, or, against the total number of tradable Seelos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seelos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Seelos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.053% of the tradable shares (for every 100,000 tradable Seelos Therapeutics shares, roughly 53 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Seelos Therapeutics.
Find out more about how you can short Seelos Therapeutics stock.
Seelos Therapeutics share dividends
We're not expecting Seelos Therapeutics to pay a dividend over the next 12 months.
Have Seelos Therapeutics's shares ever split?
Seelos Therapeutics's shares were split on a 1:30 basis on 23 January 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Seelos Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Seelos Therapeutics shares which in turn could have impacted Seelos Therapeutics's share price.
Seelos Therapeutics share price volatility
Over the last 12 months, Seelos Therapeutics's shares have ranged in value from as little as $0.5603 up to $6.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seelos Therapeutics's is 3.0918. This would suggest that Seelos Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seelos Therapeutics overview
Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. .
Stocks similar to Seelos Therapeutics
Seelos Therapeutics in the news
First Week of September 17th Options Trading For Seelos Therapeutics (SEEL)
10 Best Psychedelic Stocks to Buy Now
Seelos Therapeutics to Participate in Two Investor Conferences in August
Frequently asked questionsWhat percentage of Seelos Therapeutics is owned by insiders or institutions?
Currently 4.851% of Seelos Therapeutics shares are held by insiders and 26.812% by institutions. How many people work for Seelos Therapeutics?
Latest data suggests 13 work at Seelos Therapeutics. When does the fiscal year end for Seelos Therapeutics?
Seelos Therapeutics's fiscal year ends in December. Where is Seelos Therapeutics based?
Seelos Therapeutics's address is: 300 Park Avenue, New York, NY, United States, 10022 What is Seelos Therapeutics's ISIN number?
Seelos Therapeutics's international securities identification number is: US81577F1093 What is Seelos Therapeutics's CUSIP number?
Seelos Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03832V109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert